Furthermore, studies have also revealed that a combination of ampelopsin with ERK, JNK inhibitors and the reactive oxygen species scavenger, NAC resulted in reversal of ampelopsin-induced ERK and JNK activation and also sensitized the anti-tumorigenic effect of ampelopsin on Non-small cell lung cancer (NSCLC) cells, thus prove to be an effective strategy for preventing NSCLC proliferation [114]. This evidence concerns the gene MAPK8 and non-small cell lung carcinoma.